The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.

As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.

But camizestrant’s use could depend on uptake of monitoring – for now.

Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.

Any hopes of differentiation could come down to side effects.

Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.